Credentials

Dana-Farber Cancer Institute and Harvard Medical School

Boston, Massachusetts
Professor, Medical Oncology/Molecular and Cellular Oncology (DFCI)
Professor of Medicine, Harvard Medical School

Research Projects

Brain metastasis is one of the most devastating diagnoses in breast and other cancer types
with detrimental effects on clinical outcomes. This is in part due to the special challenges
associated with the treatment of brain metastases, including ineffective drug delivery due to
the special microenvironment of the brain as well as the extreme heterogeneity (different types) of cancer cells driving therapeutic resistance.

To tackle these challenges, Dr. Kornelia Polyak, a pioneer of the tumor microenvironment (TME) and tumor heterogeneity, is leading a collaboration with Dr. Valerie Weaver, also a pioneer in the TME and the physical properties of cancer cells.

The research is investigating how changes in environmental stress such as lack of nutrients or low oxygen, alters the sugar molecules attached to cancer cells of primary tumors compared to those attached to brain metastatic cancer cells. These changes can alter the cancer cell’s response to treatment, the ability of immune cells to recognize the cells, and the stiffness of the tumor, which affects drug delivery.

IMPACT
The role of sugar coating and variability in stress responses in cancer are largely unexplored scientific areas of cancer research with high clinical impact for positive therapeutic outcomes. The successful completion of this research will lay the foundation of combination therapies targeting both cancer cells and their microenvironment for the more effective treatment of brain metastatic disease.

Background

Kornelia Polyak, M.D., Ph.D., is a Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School. She received her M.D. in 1991 from Albert Szent-Gyorgyi Medical University in Szeged, Hungary. In 1995, she received her Ph.D. in cell biology and genetics from Cornell University Graduate School of Medical Sciences, New York, New York. She completed post-doctoral studies in cancer genetics at Johns Hopkins Oncology Center in Baltimore, Maryland in 1998 prior to joining the faculty at DFCI and Harvard.

Dr. Polyak is an internationally recognized leader of the breast cancer research field. Her laboratory is dedicated to the molecular analysis of human breast cancer with the goal improving the clinical management of breast cancer patients. Her lab has devoted much effort to develop new ways to study tumors as a whole and to apply interdisciplinary approaches. She has also been successful with the clinical translation of her findings including the testing of efficacy of JAK2 and BET bromodomain inhibitors for the treatment of triple-negative breast cancer in clinical trials.Dr. Polyak has received numerous awards including the Paul Marks Prize for Cancer Research in 2011, the 2012 AACR Outstanding Investigator Award for Breast Cancer Research, and the Rosalind Franklin Award in 2016. She was elected as a Fellow to the AAAS in 2019 and to the AACR Academy of Fellows in 2020. She is also a 2015 recipient NCI Outstanding Investigator award and is a recipient of the 2020 Distinguished Alumna Award from Weil-Cornell.

Our approach emphasizes a collaborative, team environment to accelerate new breakthroughs.

Collaborator:

Valerie M. Weaver

Accelerate innovative research like this and help save cancer patient lives.

Cancer Type Areas

Related Updates

What is Genomic Sequencing, and Who Can Benefit?

Breast Cancer Survivors Need to Take Actions to Reduce Their Increased Risk of Cardiovascular Disease

High Fiber Diet May Aid Melanoma Treatment